Literature DB >> 10591692

Improving reperfusion after myocardial infarction.

I B Menown, A A Adgey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10591692      PMCID： PMC1117244          DOI： 10.1136/bmj.319.7224.1513

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  12 in total

1.  Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group.

Authors:  E M Ohman; R M Califf; E J Topol; R Candela; C Abbottsmith; S Ellis; K N Sigmon; D Kereiakes; B George; R Stack
Journal:  Circulation       Date:  1990-09       Impact factor: 29.690

2.  Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators.

Authors:  E M Antman; R P Giugliano; C M Gibson; C H McCabe; P Coussement; N S Kleiman; A Vahanian; A A Adgey; I Menown; H J Rupprecht; R Van der Wieken; J Ducas; J Scherer; K Anderson; F Van de Werf; E Braunwald
Journal:  Circulation       Date:  1999-06-01       Impact factor: 29.690

3.  Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators.

Authors:  E M Ohman; N S Kleiman; G Gacioch; S J Worley; F I Navetta; J D Talley; H V Anderson; S G Ellis; M D Cohen; D Spriggs; M Miller; D Kereiakes; S Yakubov; M M Kitt; K N Sigmon; R M Califf; M W Krucoff; E J Topol
Journal:  Circulation       Date:  1997-02-18       Impact factor: 29.690

4.  Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study.

Authors:  N S Kleiman; E M Ohman; R M Califf; B S George; D Kereiakes; F V Aguirre; H Weisman; T Schaible; E J Topol
Journal:  J Am Coll Cardiol       Date:  1993-08       Impact factor: 24.094

5.  Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis.

Authors:  S Roux; S Christeller; E Lüdin
Journal:  J Am Coll Cardiol       Date:  1992-03-01       Impact factor: 24.094

6.  Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial.

Authors: 
Journal:  J Am Coll Cardiol       Date:  1998-12       Impact factor: 24.094

Review 7.  New antiplatelet agents: platelet GPIIb/IIIa antagonists.

Authors:  B S Coller; K Anderson; H F Weisman
Journal:  Thromb Haemost       Date:  1995-07       Impact factor: 5.249

8.  Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1988-08-13       Impact factor: 79.321

9.  Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.

Authors:  T Yasuda; H K Gold; J T Fallon; R C Leinbach; J L Guerrero; L E Scudder; M Kanke; D Shealy; M J Ross; D Collen; B S Coller
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

10.  Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation.

Authors:  H K Gold; B S Coller; T Yasuda; T Saito; J T Fallon; J L Guerrero; R C Leinbach; A A Ziskind; D Collen
Journal:  Circulation       Date:  1988-03       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.